Shareholder rights law firm Robbins LLP announces it is investigating whether certain officers and directors of Innate Pharma S.A. (NASDAQ: IPHA) violated federal securities laws. Innate Pharma S.A. is a biotechnology company that discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally.
If you suffered a loss due to Innate Pharma's misconduct, click here.
Innate Pharma S.A. (IPHA) Accused of Misleading Shareholders about Partnership with AstraZeneca PLC
In October 2018, Innate Pharma announced a long-term strategic partnership with AstraZeneca PLC. The deal included a $100 million in milestone payments paid to Innate Pharma at the start of the first Phase 3 clinical trial for monalizumab. Throughout 2019 and early 2020, Innate not only confirmed the $100 million payment, but also affirmed the results of the trial as being on track. On September 8, 2020, the Company announced a change to the $100 million payment. Instead of a one-time payment at the start of the first Phase 3 clinical trial, Innate would receive $50 million at the start, and an additional $50 million after the interim analysis demonstrated a pre-defined threshold of clinical activity. On this news, Innate Pharma's ADS's fell 26.6%, to open at $4.82 on September 8, 2020, continued to decline throughout the day to close at $4.45, and has yet to recover.
Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Innate Pharma settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005767/en/